Small Cell Lung Cancer
Conditions
Brief summary
This study was designed to investigate the efficacy and side effects of combining erlotinib with classical EC/EP chemotherapy regimens.
Detailed description
Lung cancer is a common malignant tumor that poses a serious threat to human health. Small cell lung cancer accounts for about 20% of lung cancer. Precision medicine has recently been perfectly interpreted in many tumor types, but the treatment of small cell lung cancer is still bleak. The EC/EP regimen is the most classic chemotherapy regimen for small cell lung cancer with good results but is prone to drug resistance. In 2018, with the development of immunotargeting therapy, small molecule multi-target anti-angi drugs, PARP inhibitors, new chemotherapy drugs, etc., the treatment of small cell lung cancer has ushered in a new dawn. As a kind of highly selective multi-target anti-angiogenic TKI drugs,Anlotinib Hydrochloride is a kind of 1.1 innovative drugs with independent intellectual property rights in China, mainly acting on VEGFR, PDGFR, FGFR and c-Kit. The latest ALTER1202 study confirms that anlotinib is significantly improved for PSC and ORR in SCLC patients who have previously received at least 2-line chemotherapy. OS data is not yet mature, but the benefits of the anlotinib group were observed. The adverse effects of anlotinib were consistent with expectations, no new adverse events were found, and safety was tolerated. Nowadays, the effective combination of traditional chemical therapy with molecular targeting and immunotherapy is the future development direction of lung cancer treatment. Therefore, this topic is designed to combine the efficacy of safety and safety with the treatment of anlotinib with the classic EC/EP chemotherapy regimen. Expected to get longer PFS and OS for patient benefit.
Interventions
DRUGAnlotinib Hydrochloride
Best supportive care
Sponsors
Chifeng Municipal Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. patients 18-75 years of age. 2. A metastatic or recurrent advanced SCLC confirmed by histology or cytology and did not receive any other treatment; 3. a measurable disease 4. an Eastern Cooperative Oncology Group PS of 0-1; 5. an estimated survival duration of \>6 months;
Exclusion criteria
1. Have used erlotinib or other anti-vascular targeted drugs (eg, Endo, bevacizumab, etc.)2. Patients who have been treated with chemotherapy or radiotherapy for previous tumors.3.Have appeared or merged with other tumors within 5 years.4.Patients with no measurable lesions; 5.any severe and uncontrolled disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | nine months | progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| safety assessed by Adverse reactions | 12 months | Adverse reactions |
| OS | 12 months | overall survival |
| ORR | 12 months | Objective Response Rate |
| DCR | 12 months | disease control rate |
Contacts
Primary ContactHongbo JI, postgraduate
Backup ContactLele Wang, Bachelor
Outcome results
None listed